The exercise program OnTrack is feasible, effective and
cost-effective for patients with early stage breast cancer
undergoing chemotherapy. Onco-Move is a viable alternative for
patients unwilling or unable to follow the intensive OnTrack
program. "These programs are ready to be implemented in daily
clinical practice," states Hanna van Waart, based on her PhD
research. She will defend her thesis on November 30th at the
University of Amsterdam.
More and more patients survive cancer, thanks to improved
treatments and earlier and better diagnosis. However, during and
even long after treatment patients can experience a wide range of
side effects as a result of the disease and its treatment. These
include fatigue and reduced physical fitness.
Van Waart studied the (cost)effectiveness of the exercise
programs Onco-Move (a home-based, low-intensity physical activity
program) and OnTrack (a supervised, moderate-to-high intensity
exercise program) in patients undergoing adjuvant chemotherapy.
Patients with early stage breast cancer in both Onco-Move and
OnTrack had less decline in cardiorespiratory fitness, better
physical functioning, and experienced less nausea, vomiting and
pain compared with usual care. A smaller percentage of patients in
OnTrack required chemotherapy dose adjustments than those in the
usual care or Onco-Move groups. Both intervention groups returned
earlier, and for more hours per week, to work than the control
OnTrack is the more effective of the two interventions.
Onco-Move represents a viable alternative for women who are unable
or unwilling to follow the higher intensity program. Van Waart
recommends the programs be implemented in clinical practice.
Details of the defense
Hanna van Waart will defend her thesis on Thursday November 30th,
at 12.00. Location: Agnietenkapel, Oudezijds Voorburgwal 229 -
231, Amsterdam. The title of her thesis is: Physical Exercise
during Adjuvant Chemotherapy. Promotors: Neil Aaronson and Wim
van Harten (Netherlands Cancer Institute). Copromotors: Martijn
Stuiver and Gabe Sonke (Netherlands Cancer Institute).